AMED SCARDA「ワクチン開発のための世界トップレベル研究開発拠点の形成事業」合同シンポジウム

Masaki Ishibashi¹, *日永田 純一¹, Hidetoshi Hamamoto¹ (1. MedRx Co., Ltd. (Japan))

*Hirotoshi Adachi^1,2, Uros Kascak¹ (1. PassPort Technologies, Inc. (United States of America), 2. PassPort Technologies Japan, Inc. (Japan))

Takayuki Nakamura¹, *Yuki Katagiri¹, Yasuyuki Shiraishi¹, Takashi Kamishita², Toshiaki Takagi², Natsumi Kodake², Takashi Miyazaki² (1. TaiseiKako Co,.Ltd (Japan), 2. TOKO YAKUHINKOGYO CO.,LTD. (Japan))

*Yuichi Yoshimura¹ (1. Nipro Corporation (Japan))

*Tetsuo Yoshida^1,2, Rena Akahori^2,3, Akiko Yanagiya², Naoki Matsumoto², Daichi Matsuura², Hayato Sato², Hiroaki Murakami², Tomohiro Sawadaishi², Yanwen Feng², Jun Nihira², Satoshi Abe², Kazuyuki Nakashima² (1. Axcelead, Inc. (Japan), 2. ARCALIS, Inc. (Japan), 3. Hitachi, Ltd. (Japan))

*都築 拓¹, Tsuyoshi Tatsukawa¹, Yosuke Ozawa² (1. Epistra Inc. / cSIMVa Chiba University (Japan), 2. Epistra Inc. (Japan))

*Suni LEE¹ (1. THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY (BIKEN Foundation) (Japan))

*Yuichi Kida¹, Kaoru Kobayashi¹, Kenta Fukuda¹, Nobiko Takayama¹, Takateru Nozaki¹, Misako Iwai¹, Kaoru Kobayashi¹, Katsuyoshi Takayama¹ (1. ADTEC Co.,LTD. (Japan))

masahiro oda¹, *PeiQing Zhang¹ (1. Global Life Science Technologies Japan (Cytiva) (Japan))